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INTRODUCTION 
Organophosphorus poisoning is the most common poi-
soning in India and it is a common emergency health 
problem worldwide, particularly in developing coun-
tries and common means of attempting suicide be-
cause of its easy availability  *1, 2+. It is one of the most 
common cause of severe toxicity and death with more 
than 3,00 ,000  death each year in developing countries 
*3+. Organophosphorus compounds most commonly 
used are dimethoate, dichlorovas, monocrotophos, 
chlorpyrifos, glyphosate, profenofos, malathion. Organ-
ophosphorus compounds inhibit both cholinesterase 
and pseudocholinesterase activities. The inhibition of 
acetylcholinesterase causes accumulation of acetylcho-
line at synapses and the resulting overstimulation of 
neurotransmission at the neuromuscular junction. It 
disturbs transmission at parasympathetic nerve end-
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ings, sympathetic ganglia, neuromuscular endplates 
and CNS region *4, 5+. OP poisoning compound produce 
their effects by inhibiting the action acetylcholine ester-
ase enzyme, which leads to an increase in acetylcho-
line, in preganglionic parasympathetic receptors 
(muscarinic action), sympathetic preganglionic synap-
ses including adrenal medulla and neuromuscular junc-
tion (nicotinic action) *6+. 
Early diagnosis and appropriate treatment is often life-
saving. Atropine is the mainstay of treatment of effects 
mediated by muscarine sensitive receptors. The prima-
ry outcome measure was mortality and secondary out-
come measure were time to atropinization, total dose 
of atropine required, incidence of atropine toxicity, 
incidence of interrmediate syndrome and duration of 
hospitalization *7+.  
MATERIALS AND METHODS 
Study design: An open-label randomized Clinical trial. 
Ethical approval: The study was approved by the insti-
tutional ethics committee and informed consent was 
taken from the patient/guardian. 
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Study location: Study was conducted in Shri B. M. Patil 
Medical College Hospital & Research Centre, Vijayapura 
(BIJAPUR), Karnataka, India 
Study duration: study was conducted from November 
2015 to June 2017. 
Sample size: 108 patients were included in the study. 
Data of patients who are enrolled in the study collected 
from patient fulfilling inclusion and exclusion criteria 
attended   both in ICU (Intensive care unit) and Emer-
gency Ward.   
Inclusion criteria: History of organophosphate poison-
ing (within 48hours of organophosphate poisoning and 
above age >18years) or signs of organophosphate poi-
soning (at least one of the following four signs bron-
chorrhea, miosis, fasciculation, bradycardia) and low 
serum cholinesterase level(less than 25%of normal) 
with moderate to severe poisoning. 
Exclusion criteria: Admission after 48hours of poison-
ing, carbamates or other poisonings and patients with 
mild poisoning, patient with known systemic illness like 
malignancy, chronic lung disease, renal or hepatic dis-
ease and Pregnancy. 
Methodology: An open  label randomized clinical trial 
was conducted in SHRI B.M.PATIL MEDICAL College 
Hospital and Research Centre, Vijayapura  (BIJAPUR), 
KARNATAKA, INDIA IN 108 hospitalized individuals.  The  
patients were randomly divided into two groups (group 
A) SHRI B M PATIL MEDICAL COLLEGE AND Hospital and 
(group B) SOUTH ASIAN CLINICAL TOXICOLOGY RE-
SEARCH COLLABORATION, we compared  two  groups 
that used a titrated dosing protocol based on a struc-
tured monitoring sheet for atropine infusion with an-
other group using an ‘ad hoc’ regimen. The aim was to 
compare the efficacy and safety of conventional bolus 
doses with individualized incremental doses of atropine 
for atropinization, followed by continuous atropine 
infusion for management of OPC poisoning.  
Out of 108 patients 54 patients received conventional 
bolus dose atropine (group A) and 54 patients received 
rapidly incremental dose of atropine followed by infu-
sion (group B). 36 patients analyzed in group A and 32 
patients in group B for moderate to severe poisoning. 
Assessment of severity of poisoning: Muscarinic: Brad-
ycardia, hypotension, bronchospasm, miosis, bronchor-
rhea, increased salivation, lacrimation, blurred vision, 
Figure 1. Consort Flow Diagram 
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nausea, vomiting, abdominal pain, diarrhoea, fecal and 
urinary incontinence, sweating *8, 9+. 
Nicotinic: Muscle fasciculation, cramping, weakness, 
diaphragmatic failure *10+. 
CNS: Anxiety, restlessness, confusion, ataxia, seizure, 
insomnia, dysarthria, tremor, coma *13+.  
GROUP A:  
The number of patients received increasing doses of 
Injection Atropine 2-3mg every 10-15 minutes depend-
ing on severity of signs and symptoms as decision made 
by treating clinician.  This was repeated every 10 to 15 
min until signs of atropinization were clinically evident 
(clear chest on auscultation with resolution of bron-
chorrhea, heart rate of >100 beats per minute, systolic 
blood pressure >90 mmHg, dry axillae and pupils >2mm 
in diameter) *14+. 
Injection Atropine 1cc= 0.6mg, that means 2-5cc of 
atropine had been repeated every 10-15 minutes until 
signs of atropinization*15+. This is followed by either 
intravenous infusion or bolus or intramuscular route 
for maintenance every hourly according to clinically 
assessed and the subsequent dosing with atropine in-
jections was individualized either by decreasing the 
dose or increasing the duration in between doses as 
per the preference provided as features of atropiniza-
tion were still present*16, 17+.  
If one or all of these features were absent, the dose or 
frequency of atropine was increased as per the prefer-
ence of the treating clinician. Atropinization was main-
tained for at least 24 hour until clinical recovery, i.e. till 
resolution of all features of cholinergic crisis occur. 
Following the initial atropinization, patients had to be 
reassessed for the five features of atropinization every 
15 minutes. When atropinization could not be achieved 
(bronchospasm or bradycardia, sweating and miosis) if 
still present, further bolus of atropine was adminis-
tered. After atropinization, patients were observed at 
least every hour for 6 hours *19+. 
If atropine toxicity developed (confusion, pyrexia, ab-
sent bowel sounds; all three should be present), atro-
pine was stopped and patients were closely monitored. 
Figure 2.  Treatment Procedure: *11, 12, 14+  
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In case of a decline in heart rate to less than 100 b/m 
on day 1 and 60 b/m on day 2 onwards 2-3cc i.e. 1-2mg 
atropine intravenous boluses/ Intramuscular to be re-
peated every 15 minutes.  
In case of persistent tachycardia HR > 120bpm atropine 
infusion can be lowered by 1 mg/h or assessed clinical-
ly. 
GROUP B: 
It consists of an initial bolus of 1.5 to 3 mg of atropine 
with doses doubling every 5 minutes until atropiniza-
tion is achieved. Clearing of chest on auscultation was 
used as the primary endpoint of atropinization *18+. 
Following that an infusion is given with a rate that is 
estimated from the size of the initial dose required to 
achieve atropinization. This is typically in the range of 1 
to 2 mg/hour. Incremental dose was defined as 1.5–3 
mg atropine by intravenous (IV) infusion, repeating the 
dose every 5 minutes interval, doubling the dose each 
time to the point of atropinization occurs, followed by 
10–20% of atropine required for atropinization, every 
hour by IV infusion*19, 20, 21+. 
Example -2, 4, 8, 16,…etc   every five minutes until atro-
pinization, after initial atropinization, patients were 
maintained on an atropine infusion, using 10% of the 
atropine required to load the patient given per hour 
e.g. if atropine required for atropinization was 15 mg, 
1.5 mg was Infused each hour by mixing the amount of 
atropine required for 24 h with 1,000 ml normal saline 
and giving it at a rate of 40 micro drops per minute as a 
continuous infusion *22-25+.  
Table 1. Group B observation chart 
Supriya et al.  Comparative study of commonly practiced atropinization regimens in acute organophosphorus compound poisoning. 
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Common treatment followed to both the groups: The 
poisoned patients were divided into three categories, 
mild, moderate and severe. Gastric lavage and ade-
quate ventilation maintained. The stabilization was 
carried out in the emergency ward and patients were 
monitored using continuous ECG monitor, pulse oxime-
try and blood pressure, clinically assessed dehydration 
corrected with Intravenous fluids, oxygenation and 
catheterization before atropine was given. Pam 
(oximes) had been given to both groups. Treatment 
with  pralidoxime was repeated as a bolus at the same 
dose and rate as the initial dose every 8 h for 48 h in all 
surviving patients as per standard practice *26+.  
Evidence of pralidoxime toxicity including tachycardia, 
muscular rigidity, neuromuscular blockade, hyperten-
sion, laryngospasm and mild hepatitis was recorded 
and managed by reducing the subsequent dose of pra-
lidoxime and/or atropine as appropriate. Atropinization 
followed according to group decided by treating team. 
Other supportive treatment had been made as for re-
quirement like eye care, oral care, endotracheal tube 
care. Tracheostomy done in some patients who had 
longer period of ventilator supports. Routine investiga-
tions includes complete blood count, renal function 
test, liver function test, chest X RAY, random blood 
sugar, most importantly serum cholinesterase, which is 
one of the prognostic indicator for OPC poisoning *27+. 
Diagnosis of intermediate syndrome (IMS): Intermedi-
ate syndrome was defined as proximal muscle weak-
ness of Grade 3 or less, 72 hours after poisoning with or 
without requirement of mechanical ventilation. All pa-
tients were monitored for early signs of IMS due to OPC 
poisoning. Signs of IMS were weakness of neck flexion, 
difficulty in lifting the head off the pillow, use of acces-
sory muscles of respiration, nasal flaring, tachypnea, 
sweating, cranial nerve palsies and proximal limb mus-
Table 2. Demographic history; According to patient age, sex distribution, occupation, nature of poison, prior hospital-
ization, prior treatment and time between ingestion and hospitalization in OPC poisoning in group A and group B.  
Supriya et al.  Comparative study of commonly practiced atropinization regimens in acute organophosphorus compound poisoning. 
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cle weakness with retained distal muscle strength. IMS 
was managed by supportive measures including intuba-
tion and ventilation if required. The patients were dis-
charged after a minimum of 24 h of observation post 
cessation atropine if they had no residual features of 
OPC poisoning *28-30+. 
Markers of atropine toxicity: Confusion, pyrexia, absent 
bowel sounds or urinary retention were used mainly in 
the diagnosis of atropine toxicity *25-30+. 
Statistical analysis: Data were analyzed using SPSS soft-
ware v.23.0. and Microsoft office. Chi-square/Freeman- 
Halton Fischer exact test was employed to determine 
the significance of differences between groups for cate-
gorical data. The differences of the means of analysis 
variables between two independent groups was tested 
by unpaired t test, p value was calculated and p value 
<0.05 were considered to be statistically significant. 
RESULTS 
 
Graph 1. Atropine dose Day 1. 
ATROPINE DOSES       GROUP A     GROUP B        P VALUE 
      MEAN ±SD     MEAN ±SD   
0 -2 hours       6.2 ± 2.7    18.2 ± 8.8     <0.001* 
3-4 hours       6.0 ± 3.5    3.6 ± 2.8      0.003* 
5-6 hours       5.9 ± 3.2    5.2 ±  3.1      0.343 
7-8hours       6.0 ± 3.7    6.5 ±  3.2      0.552 
9-24 hours       29.4 ± 17.4   33.8± 11.6      0.227 
DAY 1 total       52.1 ± 22.7   67.3± 18.1      0.003* 
DAY 2       23.6 ± 18.5   31.5± 11.8      0.047* 
DAY 3       16.9 ± 14.5   23.1± 13.6      0.091 
DAY 4       12.7 ± 14.1   19.3± 14.8      0.101 
DAY 5      10.8 ± 17.2   17.7± 11.9      0.209 
DAY 6      11.5 ± 13.2   19.3± 9.6      0.175 
DAY 7       8.7  ± 13.5   13.3±10.3     0.484 
DAY 8      14.7 ± 19.9   25.8 ± 4.2     0.522 
Table 3. Atropine dose between study groups among 36 patients in group A and 32 patients in group B analyzed 
for moderate to severe poisoning  
Outcome 
Group A Group B Total 
 P value 
N % N % N 
Complete recovery 31 50.8 30 49.2 61 0.301 
Recovery with complications 5 62.5 3 37.5 8 0.564 
Intermediate syndrome 9 69.2 4 30.8 13 0.048* 
Atropine toxicity 9 64.3 5 35.7 14 0.027* 
Mortality 5 71.4 2 28.6 7 0.031* 
Table 4.  Outcomes in terms of recovery, complication, atropine toxicity, mortality and IMS  
Supriya et al.  Comparative study of commonly practiced atropinization regimens in acute organophosphorus compound poisoning. 




Graph 2. Day 1 to Day 8. 
 
Features on enrollment, there were 54 patients en-
rolled in group A and 54 in group B. 36 patients in 
group A and 32 patients in group B analyzed for moder-
ate to severe poisoning.  
Initial atropinization, In group A the mean atropine 
required for initial atropinization of a patient was 
19.9mg.The mean time requires for atropinization was 
5.8hours that is 348 minutes. Minimum time taken for 
atropinization was 2hours and maximum 18hours from 
7.2mg to 43.2mg. Total mean atropine given initial 
24hrs was 52.1 in 24hours.In group B, the mean atro-
pine required for initial atropinization was18.2mg.The 
time required for atropinization was 28.1 minutes that 
is less than 1hour. Mean atropine in day 1was 67.3mg. 
DISCUSSION 
Atropine is the universally accepted specific treatment 
in the management of anticholinesterase poisoning *18
-20+. In the study we found that rapid atropinization 
followed by atropine infusion greatly reduced mortality 
when compared to standard treatment with boluses of 
atropine 4 (11.1%in group A) versus 2 (6.3%in group B). 
When we compare group A, 4 of patients died  com-
pared to 2 in group B. In other study done previously 
had same outcomes where 45 cases of organophospho-
rus poisoning study showed that continuous infusion 
significantly reduced mortality compared to inter-
mittent boluses (23.5% to 8.8%; p<0.05) *21-22+. 
The similar study conducted on 131 sample shows that 
rapid incremental dose atropinization followed by atro-
pine infusion reduces mortality and morbidity from 
OPC poisoning and shortens the length of hospital stay 
and recovery advantage over conventional incremental 
bolus doses alone (24.7% versus 8%;p<0.05)*23+. The 
study conducted on 56 patient shows frequency of at-
ropine toxicity in the rapid incremental regimen fol-
lowed by infusion (1.8%) was considerably lower than 
conventional regimen *24+. 
The relatively few formal trials in OPC poisoning that 
have been done to make it clear that early antagonism 
of OPC toxicity is associated with better outcome *25+. 
Full and early atropinization is ideal as delayed atropin-
ization can result in death from central respiratory de-
pression, bronchospasm, bronchorrhea, severe brady-
cardia and hypotension *26+.The time interval between 
exposure to OPC poisoning and onset of symptoms of 
poisoning varies with route and degree of exposure. 
Following massive ingestions, the symptom appear 
within several minutes*27+.With smaller amounts, in 
most instances, symptoms appear within 30minute of 
exposure and almost always in less than 12hrs*28+. 
In our series, the earliest presentation of an individual 
with features of toxicity was within 30minutes of inges-
tion of OPC, although 25% took more than 4hrs to 
reach the hospital. Delay in discovery and transport to 
the hospital as well as differences in treatment seeking- 
behaviour can cause differences in presentation and 
increased mortality. Local effects on eyes and respira-
tory tract may appear within minutes. After ingestion 
of OPC, the initial symptom may be gastrointestinal or 
may be related to any other organs affected *26+. Regi-
men B was found to be associated with a lower risk of 
developing IMS (P<0.05) *28-30+.Ventilation support 
was needed for 18 patients out of 68.Of these 12, sur-
vived. In other studies, the survival rate in OPC poison-
ing requiring mechanical ventilation varied between 
13% and 50%in a variety of setting. Ventilator support 
was required in significantly fewer patients treated 
with regimen B *30-34+. 
The occurrence of atropine toxicity also compared be-
tween the treatments groups *35-38+. Patient treated 
with conventional bolus dose were found to be more at 
risk of developing atropine toxicity (25%versus 12.5%, 
p<0.05%).Previous studies have found similar rates 
with bolus regimen (26%) *35-40+. 
CONCLUSION 
Use of atropine for organophosphorus poisoning given 
by individualized incremental bolus doses followed by 
continuous infusion has several advantages over con-
ventional incremental bolus doses alone. Early atropin-
ization reduces mortality and atropine toxicity which 
leads to better hospital outcome and recovery. Accu-
rate and frequent monitoring is required in convention-
al incremental bolus dosing regimen for atropinization 
and toxicity. 
Limitation: The study was done on small number of 
patients and involved moderate to severe poisoning. 
Many patients enrolled into the study were referred 
from a peripheral hospital and treatment received 
there might have had some influence on the require-
ment of atropine. 
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